Polifarma completes portfolio in Gastro area with Gelsectan®

Polifarma and Devintec Pharma signed an agreement for the distribution of Gelsectan®, a medical device for the management of irritable bowel syndrome. 

Polifarma Spa expands its portfolio in the gastrointestinal area thanks to a long-term distribution agreement with Devintec Pharma Sagl, a Lugano-based pharmaceutical company that is a pioneer in the research and development of substance-based medical devices and owner of the Gelsectan® brand. 

Gelsectan® is a medical device with natural functional ingredients useful “for the restoration of intestinal function in patients suffering from alterations due to irritable bowel syndrome (IBS) that may be related to intestinal hypersensitivity or to the intake of certain medications, to alleviate and prevent symptoms such as chronic or relapsing diarrhea, abdominal distension, pain, bloating and flatulence”. 

Polifarma continues its investment in the product portfolio in the gastrointestinal area, driven by the increasing incidence of disorders in this area. Irritable bowel syndrome, in fact, is one of the most common functional gastrointestinal disorders, according to data from the Istituto Superiore di Sanità, affecting about 10% of the population and mainly affecting women, mainly in the 20-50 age group.  It is a functional bowel condition characterized by colonic muscle spasms, intestinal malfunction and affects the large intestine. 

Polifarma CEO Andrea Bracci comments on the newly signed agreement as follows - “With the entry of Gelsectan®, Polifarma confirms its interest in strengthening its product list dedicated to intestinal pathologies, consisting of drugs, medical devices and dietary supplements, reaffirming its focus on patients suffering from IBS and requiring long-term treatment. This is a chronic disease of a cyclical nature characterized by recurrent symptoms and associated with high costs for the patient and society. The collaboration with Devintec Pharma will benefit people with this disorder and strengthen Polifarma's position in the gastrointestinal health sector. We will continue to actively seek opportunities to expand our product portfolio and ensure that patients have access to high-quality solutions”.  

Rossana Sidoti, as general manager of Devintec, says, “Gelsectan® represents one of the most important products in Devintec Pharma. It was the company's first product to be launched on the European market to treat patients with irritable bowel syndrome (IBS) thanks to a new patented solution that has demonstrated high efficacy on all symptoms, thanks to an innovative mechanism of action that acts on the etiology of this pathology, namely intestinal hyperpermeability. A few years after its launch, Gelsectan has helped patients in more than 23 countries and was recently mentioned in the European Guidelines. We are pleased to collaborate with Polifarma because it will enable us to help even more patients with IBS. Polifarma is an established company in the treatment of gastrointestinal diseases, with a strong presence in Italy. It represents the ideal partner for Devintec Pharma in a new phase of growth, in an increasingly competitive global context. The union of two important realities, with different histories but animated by the same values, i.e., attention to the patient and the guarantee of innovative therapeutic solutions, will also allow to invest in Devintec Pharma's future, fostering the research and development of new products and contributing to the company's global growth. This is an agreement that will enable the two companies to strengthen their positioning in the gastrointestinal sector, as well as combine expertise and experience”.